Neurovascular Devices Market Size $4.2B to $10.2B (2026–2036) Q2 2026 Updated | Meridian Consensus

Decision-grade Market IntelligenceAny market · any geography

Layers Companies Methodology Pricing About Contact

Healthcare

currentUpdated yesterdayNext refresh May 29Live · since 40d ago

Boardroom-ready · 8 languages

Neurovascular Devices Market

Name: Neurovascular Devices Market
Creator: Meridian Consensus
Published: 2026-04-13T09:20:55.814Z
License: https://www.meridianconsensus.com/editorial-policy

Valued at $4.2B in 2025, growing at 8.4% to $10.2B by 2036. Moderately concentrated; the top three incumbents hold , led by .

Request the preview PDF

A 57-page institutional preview of the Neurovascular Devices Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Takeaways

North America · 44% revenue share ($1.8B)·Stryker Corporation · 25% share ($1.1B)·Comprehensive Stroke Centers (IDN GPO contract) · 46% of market·Growth of $6.0B · 2025–2036

What are you trying to answer?

Smart-routing TOC · 3 intents

U.1

Strategy / corp dev / market entry

Sizing the opportunity

How big is the Neurovascular Devices today, where is it growing fastest, and what is its three-path-triangulated forecast?

Size rigor + forecast →

U.2

Investment / M&A / equity research

Reading the competitive landscape

Who leads the Neurovascular Devices, by how much, and which incumbents are losing share to which challengers?

Competitive landscape →

Full analysis · 30 chapters

Inside the commissioned report.

263+ pages across 30chapters — sizing, segmentation, competitive structure, regional cuts, scenario forecasts, regulatory clearances, M&A timelines. Every angle a senior buyer asks about, in one place.

01 / 306 pp

Executive Brief

Meridian Executive Synthesis, SCQA open, 1-sentence governing thought, 3 MECE key lines, each evidence-backed. The single page institutional buyers read first.

02 / 3014 pp

Executive Briefing

Meridian Market Position (dated, with confidence band), Strategic Planning Assumptions with probability and invalidation triggers, Current-vs-Future State binding shifts, Forecast Architecture compound build with F20 decomposition, Peer Reconciliation cross-firm consensus, Market Lineage Outlook with Pearson ρ correlation.

Same rigor · your market

This published preview · your commissioned report.

8 dimensions · side-by-side

Dimension

This published preview

Your commissioned report

01Market size & forecast

Headline 2025 figure ($4.2B) and 2036 forecast ($10.2B), year-by-year build to 2036.

Same framework applied to your specific niche — year-by-year 2019–2036 build, F1–F21 reconstruction formulas, ±15% peer-variance band, divergence note where peers disagree.

02Competitive landscape

Analyst take · Healthcare desk

The thesis.

By Meridian Consensus Editorial Committee, Editorial Committee

May 22, 2026 · Committee-reviewed

Our view is that Stryker's 25% share understates its pricing power in thrombectomy, where reimbursement tailwinds and aging demographics should push the segment CAGR above the market average through 2030.

Stryker controlled 25% of the $4.2B market at year-end 2025, translating to roughly $1.05B in neurovascular revenue. Medtronic plc sat at 20% ($840M), and MicroVention—Terumo's interventional arm—held 14% ($588M). By our count, the top three operators command 59% of the global installed base, leaving a fragmented tail of regional players in Europe and Asia Pacific. North America accounted for 39% of 2025 sales, Europe 29%, and Asia Pacific 24%. The remaining share scattered across Latin America and the Middle East.

Two forces are compounding here. First, evolving clinical guidelines and demographic trends are expanding the treatable stroke population, and Medicare reimbursement structures continue to support mechanical thrombectomy procedures. Second, new aspiration catheter designs have entered the market, potentially shortening procedure times and widening the treatable patient pool. Thrombectomy devices—38% of the market—are the obvious beneficiary. We're tracking hospital capital expenditure budgets for Q1 2026; early reads from three large IDNs suggest double-digit increases in neuro-interventional suite allocations.

Stryker's lead in thrombectomy isn't static. The company has launched new aspiration catheter technology, and channel checks suggest competitive dynamics are shifting within complete stroke centres. Medtronic plc still owns the coil segment (legacy Boston Scientific portfolio), but coils are growing at roughly half the market rate. MicroVention has notable presence in flow diverters. Penumbra (not in the top three by total revenue) is the wildcard—reports suggest aggressive pricing in certain regions, which could migrate to North America and create margin pressure.

Market structure

Size rigor.

Addressable market, unit economics, value chain, and trade flows. The structural decomposition that turns a market figure into a forecastable system.

TAM · SAM · SOM reconciliation

vs reported: ⚠ flagged (90% variance)

01TAMTotal addressable

$5.9B

Global ceiling

Method

Top-down: served market × broader-addressable multiplier

Includes adjacent segments and currently-unaddressed geography that the served market could expand into without crossing into a different category.

Industry-typical TAM/served ratio applied to current served-market size

Strategic framing

Buyer · tech · competition · scenarios.

Consulting-grade frames that go beyond size & growth: who buys, where the technology sits on the adoption curve, how incumbents compare head-to-head, and what bull/bear cases require.

Buyer persona · decision unit

Primary buyer

Budget

Cycle

Influencers

Market dynamics

Driver

Mechanical thrombectomy expansion

DAWN, DEFUSE-3, and TENSION trials extending eligibility window; CMS coverage decisions amplifying procedure volume.

Driver

Comprehensive Stroke Center proliferation

1,200+ certified comprehensive stroke centers in US today, growing 5–8%/yr; each new center adds operator capacity for thrombectomy procedures.

Driver

Aspiration-only thrombectomy adoption

ASTER and COMPASS trials supporting first-pass aspiration as first-line; simpler workflow drives operator confidence and case volume.

Industry structure

Porter forces · SWOT.

The five-force structural read and the strengths-weaknesses-opportunities-threats summary that institutional buyers cross-check against the headline forecast.

Porter five forces

Recent industry events

Q2 2024

Search ↗

TENSION trial published — large-core thrombectomy benefit confirmed, extending mechanical thrombectomy patient population.

Q1 2025

Search ↗

Stryker completed Inari Medical acquisition ($4.9B) — neurovascular and peripheral thrombectomy market consolidating.

Adjacency

Related markets.

All markets

Competitive overlap

Markets sharing these incumbents.

3 adjacent

Thrombus Aspiration Catheter Market

$2.0B

Healthcare8.1%

4 shared incumbents

Stryker Corporation · Medtronic plc · ACANDIS · Asahi Intecc

Thrombectomy Devices Market

$1.9B

Healthcare6.5%

3 shared incumbents

Medtronic plc · MicroVention (Terumo) · Vesalio

Add-on chapters · from $79

Commission this report — then attach Layers.

Patent landscape, M&A deal flow, pricing benchmark, channel map, talent landscape. Pick at checkout. Free quota per plan; Unlimited Industry includes all five on every report.

See all Layers

Commission the full report

Pick the scope. Keep the research.

One-time purchase. No subscription traps. Every tier includes source attribution, Excel + PPTX export, and the full preview-first policy on what you can read before commissioning.

Instant access on demand

Read everything before you commission

90-day refresh included

Strategic Brief

Just this market

$799

one-time

Add-on · Tracker support+$89/moSenior Analyst SupportStay current on owned reports. Cancel any time, billed monthly.

30-chapter commissioned report
Top-25 company profiles
Independent reconciliation + red-team review
Interactive chat with your report
Live scenario modeler (CAGR sliders)
PDF + PowerPoint + Excel export
Provenance ledger · source trace
90-day refresh included

Commission this report

5-pack bundle

10-pack bundle

Any 10 markets in Healthcare

$2,999

~$300 per report

Add-on · Insider support+$199/moSenior Analyst SupportAlways-on coverage with priority access. Cancel any time, billed monthly.

Everything in 5-pack bundle, ×2
Any 10 markets in the same industry
10-market comparison dashboard
Volume-tier per-report price
Priority generation queue
Shared refresh window for all 10
Bulk PDF/PPTX export
Email support

Build 10-pack bundle

Industry unlimited

Every Healthcare market, 5 years

$8,999

5-year access · included

Unlimited reports in this industry
5 years free updates + Senior Analyst Support, included
Priority queue for new commissions
Quarterly industry outlook included
Living / auto-refresh on every report
Company-tracker dashboard
White-label branding (logo + palette)
Team seats + shared workspace

Subscribe to industry

Forecast trajectory · compositional segment build

Per-segment Bass / logistic fits composed into a total-market trajectory. Headline summary CAGR 8.4% is derived from this trajectory, not assumed flat. Show year-by-year build →Hide build ↑

Year	Value	YoY	Primary driver
2025	$4.2B	+0.0%	—
2026peak	$4.9B	+17.0%	Flow diverters (Pipeline Vantage, FRED X, Surpass Evolve) +2.7pp
2027inflection	$5.5B	+11.2%	Flow diverters (Pipeline Vantage, FRED X, Surpass Evolve) +2.3pp
2028	$6.0B	+10.2%	Stent retrievers (Trevo, Solitaire, EmboTrap) +2.1pp
2029	$6.6B	+9.3%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.9pp
2030	$7.1B	+8.5%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.8pp
2031	$7.7B	+7.7%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.7pp
2032	$8.2B	+7.0%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.6pp
2033	$8.8B	+6.4%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.5pp
2034	$9.3B	+5.8%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.5pp
2035	$9.8B	+5.3%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.4pp
2036trough	$10.2B	+4.8%	Stent retrievers (Trevo, Solitaire, EmboTrap) +1.3pp

Segment fit detail

Stent retrievers (Trevo, Solitaire, EmboTrap) — logistic · stage: inflection · RMSE 16

Penetration 22.0% in inflection band, mean YoY 10.5% — fitting logistic.

Aspiration catheters (AXS Vecta, React, SOFIA) — logistic · stage: inflection · RMSE 13

Penetration 18.0% in inflection band, mean YoY 10.5% — fitting logistic.

Embolic coils (bare-platinum + bioactive) — logistic · stage: inflection · RMSE 15

Penetration 21.0% in inflection band, mean YoY 10.5% — fitting logistic.

Flow diverters (Pipeline Vantage, FRED X, Surpass Evolve) — bass · stage: early · RMSE 147

Penetration 14.0% < 15% with non-decelerating growth — early adoption.

Intrasaccular disruptors (WEB, Contour) — bass · stage: early · RMSE 94

Penetration 9.0% < 15% with non-decelerating growth — early adoption.

Intracranial stents & support (Neuroform Atlas, LVIS, Accero) — logistic · stage: inflection · RMSE 11

Penetration 16.0% in inflection band, mean YoY 10.5% — fitting logistic.

Inflection-point notes

2027 — YoY -5.8pp vs prior year — primary driver: Flow diverters (Pipeline Vantage, FRED X, Surpass Evolve) (+2.3pp)

Competitive landscape

20 companies

#	Company	HQ	Revenue	Share
01	Stryker Corporation	Kalamazoo, MI	$1.1B	25.0%
02	Medtronic plc	Dublin, Ireland	$840M	20.0%
03	MicroVention (Terumo)	Aliso Viejo, CA	$588M	14.0%
04	Johnson & Johnson MedTech	New Brunswick, United States	$168M	4.0%
05	Penumbra	Alameda, United States	$147M	3.5%

Growth forecastUSD M

Commission

Commission your market

Don't see your specific niche? Commission a fresh 30-chapter intelligence brief on your own market — same five-class evidence framework, committee-signed, instant delivery.

30-chapter deep-dive

Top-25 company profiles

Reconciliation chapter

Red-team review chapter

Interactive chat w/ report

Live scenario modeler

Change alerts + comments

Tokenised share link

Provenance ledger

Company tracker

PDF · PPTX · Excel

White-label branding

What moves this market

Drivers

Mechanical thrombectomy expansion

DAWN, DEFUSE-3, and TENSION trials extending eligibility window; CMS coverage decisions amplifying procedure volume.

Comprehensive Stroke Center proliferation

1,200+ certified comprehensive stroke centers in US today, growing 5–8%/yr; each new center adds operator capacity for thrombectomy procedures.

Aspiration-only thrombectomy adoption

ASTER and COMPASS trials supporting first-pass aspiration as first-line; simpler workflow drives operator confidence and case volume.

Restraints

Reimbursement scrutiny on thrombectomy expansion

CMS coverage decisions on extended-window mechanical thrombectomy and large-core trial data (TENSION, SELECT2) are gating broader patient eligibility; payer cost-effectiveness reviews are tightening rather than loosening through 2027.

Center-volume learning curve

Effective thrombectomy outcomes correlate strongly with operator volume (>20 cases/yr); the 1,200 US comprehensive stroke centers cap the deliverable case volume in the near term, limiting growth to where credentialed neuro-interventionalists exist.

Request the preview PDF

A 57-page institutional preview of the Neurovascular Devices Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Meridian Consensus Digest

Free · Weekly

Not ready to commission a full report? Get our weekly briefing instead — new market sizings, thesis revisions, and reconciliation updates. Signed by the research team. No sales emails.

How this market was sized

Meridian Consensus Framework · v5

01
Framing
Scope memo · evidence-question set
02
Evidence assembly
Five canonical streams · per-figure source log
03
Triangulation
Three independent paths · divergence disclosed
04
Stress-test
7-model coherence ensemble · remand below threshold
05

Regional analysis

01North America

44%

$1.8B

02Europe

24%

$1.0B

03Asia Pacific

24%

$1.0B

04Rest of World

$336M

Country analysis

Country	Size (USD M)	CAGR	Share
USUnited States	$1.8B	5.5%	42.0%
CNChina	$588M	7.5%	14.0%
DEGermany	$294M	5.0%	7.0%
JPJapan	$252M	4.5%	6.0%
GBUnited Kingdom	$210M	5.5%	5.0%
FRFrance	$168M	5.5%	4.0%
BRBrazil	$126M	6.5%	3.0%
ROWRest of world	$798M	6.0%	19.0%

Year-by-year forecast

Year	Market size (USD M)	YoY growth
2025	$4.2B	—
2026	$4.6B	+8.4%
2027	$4.9B	+8.4%
2028	$5.4B	+8.4%
2029	$5.8B	+8.4%
2030	$6.3B	+8.4%
2031	$6.8B	+8.4%
2032	$7.4B	+8.4%
2033	$8.0B	+8.4%
2034	$8.7B	+8.4%
2035	$9.4B	+8.4%
2036	$10.2B	+8.4%

Frequently asked questions

$4.2B in 2025, scaling to $10.2B by 2036 on a 8.4% CAGR. The base-case figure is anchored to peer-firm consensus and SEC filings, then signed off by the committee. Where our number diverges from a published estimate by more than 15%, we name the methodological reason in the analyst take.

Stryker Corporation holds 25.0% on roughly $1.1B of sector revenue. Add Medtronic plc at 20.0% and MicroVention (Terumo) at 14.0% and the top three control 59%. The remaining 41% is split across regional incumbents and a long tail of acquisition candidates for any of the top three.

Comprehensive Stroke Centers (IDN GPO contract) at 46% of value. The cube spans by device sub-family / by clinical indication / by care setting & procurement path / by geography / by vendor concentration tier, with sub-segment shares anchored to peer-firm breakdowns and committee-reviewed sizing. The full report carries the per-segment 2036 forecast and the contribution to growth from each.

North America ran 44% of the 2025 pool, roughly $1.8B in absolute terms. Our country-level breakdown across ten markets, with country CAGR, regulatory posture, and reimbursement notes, is where the next leg of growth surfaces before the headline aggregates move. That sits in the full report.

Top of our list on the upside: mechanical thrombectomy expansion, with comprehensive stroke center proliferation a close second. The binding constraint over the next twenty-four months is reimbursement scrutiny on thrombectomy expansion. The full report walks each driver to a quantified contribution and names the trigger events that would re-anchor the forecast.

Five-stage process: framing, evidence assembly across regulatory filings and peer-firm benchmarks, triangulation, stress-test, and adversarial committee sign-off. Nothing publishes without the committee. Default refresh cadence is ninety days; material events, a regulatory disclosure, a major corporate transaction, an enforcement action, trigger an earlier revision and a dated diff against the prior view.

Neurovascular Devices Market

Request the preview PDF

Sizing the opportunity

Reading the competitive landscape

Inside the commissioned report.

Executive Brief

Executive Briefing

The thesis.

Size rigor.

TAM · SAM · SOM reconciliation

Buyer · tech · competition · scenarios.

Buyer persona · decision unit

Market dynamics

Porter forces · SWOT.

Porter five forces

Recent industry events

Related markets.

Inpatient Services Market

Preventive Medicine Market

Interventional Cardiology Market

Markets sharing these incumbents.

Thrombus Aspiration Catheter Market

Thrombectomy Devices Market

Commission this report — then attach Layers.

Pick the scope. Keep the research.

Strategic Brief

5-pack bundle

10-pack bundle

Industry unlimited

Market overview

Forecast trajectory · compositional segment build

Competitive landscape

Segmentation

By Device Sub-family

By Clinical Indication

By Care Setting & Procurement Path

By Geography

By Vendor Concentration Tier

Commission your market

What moves this market

Request the preview PDF

Meridian Consensus Digest

Stress-testing the thesis

Value Chain

Market Dynamics

PESTLE Analysis

Pricing Analysis

Segmentation: By Product

Segmentation: By Application

Segmentation: By Channel

Segmentation: By End User

Regional Analysis

Competitive Landscape

Company Profiles

Technology Analysis

Industry Deep Dive

Adoption Curve

Patent & IP

Funding Activity

Regulatory & Technical Requirements

Innovation Pipeline

Scenario Analysis

Market Timing & Inflection

AI Disruption & Horizon

Deal Comps & Valuation

Market Entry Playbook

Risk Assessment

Recommendations

Investment Thesis

Red Team Review

Appendix · Primary Research

Key signals

PRICED IN

UNDER-PRICED

BREAKS THESIS

Value chain map

Technology maturity

Scenario analysis

Regional analysis

Country analysis